Physician
Oncology
Dr. Bryan T. Hennessy, MD
|
|
Give Review
Bryan Hennessy works in the field of Oncology. Bryan Hennessy is a published physician. He has 39 papers published. The most current publication "Genome-wide transcriptome profiling of homologous recombination DNA repair."
Publications
- Genome-wide transcriptome profiling of homologous recombination DNA repair.
- Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer.
- Mechanistic Basis for Overcoming Platinum Resistance Using Copper Chelating Agents.
- Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors.
- Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.
- HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.
- Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithe...
- Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy.
- Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.
- 14-3-3 σ expression effects G2/M response to oxygen and correlates with ovarian cancer metastasis.
- Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo.
- Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.
- PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.
- Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy.
- Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set.
- Outcome differences between patients with node-negative breast cancer classified according to the st. Gallen risk categories.
- AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.
- Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression.
- Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer.
- Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a n...
- Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.
- Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance ...
- Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node me...
- Rak functions as a tumor suppressor by regulating PTEN protein stability and function.
- Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer.
- A systems approach to analysis of molecular complexity in breast cancer.
- Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis.
- An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
- Ovarian cancer: linking genomics to new target discovery and molecular markers--the way ahead.
- Pharmacodynamic markers of perifosine efficacy.
- Breast carcinoma with neuroendocrine differentiation and myocardial metastases.
- A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
- Trends for inflammatory breast cancer: is survival improving?
- Primary angiosarcomas of the breast.
- Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases afte...
- Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy.
- Squamous cell carcinoma of the breast.
- New approaches in the treatment of myelofibrosis.
Conditions Treated
- Secondary Malignancies
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Texas Health Science Center -
University College of Dublin National Univ SOM
Helpful Reviews
Similar Doctors
|
|
Dr. Scott E. Woodman, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Kimberly H. Koenig, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth J. Shpall, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. David Hui, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Stacy L. Moulder, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Werner A. Bleyer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Henry I. Zaleski Jr., MD
This Doctor is OpenDoctor Recommended.
|